# US Precision Medicine Market > US Precision Medicine Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Rare Diseases, Infectious Diseases), By Technology (Genomics, Proteomics, Metabolomics, Microbiomics, Bioinformatics), By End Use (Pharmaceutical Companies, Healthcare Institutions, Research Organizations, Diagnostic Laboratories) and By Product (Diagnostic Tools, Therapeutics, Genetic Testing, Data Analytics Solutions) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.97% - **2024:** $ 7.83 Billion - **2025:** $ 8.61 Billion - **2035:** $ 22.27 Billion - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Abbott Laboratories (US), Qiagen (DE), Bristol-Myers Squibb (US), GRAIL (US), Foundation Medicine (US), Novartis (CH) **Report ID:** MRFR/Pharma/13135-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** May 04, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-precision-medicine-market-14662 --- ## Market Summary ## **US Precision Medicine Market Overview** As per MRFR analysis, the US Precision Medicine Market Size was estimated at 20.79 (USD Billion) in 2023. The US Precision Medicine Market Industry is expected to grow from 23.95(USD Billion) in 2024 to 54.87 (USD Billion) by 2035. The US Precision Medicine Market CAGR (growth rate) is expected to be around 7.828% during the forecast period (2025 - 2035). ### **Key US Precision Medicine Market Trends Highlighted** The US Precision Medicine Market is rapidly evolving, driven by significant advancements in genomics and biotechnology. A key market driver is the increasing emphasis on personalized healthcare approaches, which aim to tailor medical treatments to individual patient profiles. This customization improves treatment effectiveness and patient outcomes. Additionally, the rising prevalence of chronic diseases and genetic disorders in the US fuels the demand for precision medicine solutions. The integration of artificial intelligence and machine learning in healthcare further enhances data analysis, enabling more accurate diagnostics and targeted therapies. Recent trends in the US include growing investment in research and development initiatives focusing on precision medicine. Government support and funding programs, such as those from the National Institutes of Health (NIH), encourage innovation in this field. Furthermore, collaborations between biotechnology firms, academic institutions, and healthcare providers are becoming more common, effectively pooling resources and expertise to advance precision medicine initiatives. There are considerable opportunities to be explored, particularly in the realm of health data interoperability and electronic health records. Improving the exchange of patient data can lead to better-informed clinical decisions and personalized treatment strategies. Another opportunity lies in expanding access to precision medicine for underserved populations, addressing disparities in healthcare access based on race, income, and geographic location. By enhancing accessibility, the US can ensure that all patients benefit from the advancements in precision medicine, ultimately leading to better health outcomes across diverse populations. These trends reflect the dynamic landscape of the US Precision Medicine Market as it continues to adapt and grow in response to patient needs and technological innovations. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Precision Medicine Market Technology Insights** The Technology segment of the US Precision Medicine Market is a pivotal area that harnesses advanced scientific methodologies to tailor medical treatment to individual patient profiles. Within this segment, Genomics plays a crucial role by analyzing genetic variations to inform treatment decisions, thus driving personalized therapies. Proteomics focuses on the study of proteins and their functions, facilitating the identification of biomarkers for disease and treatment response. Metabolomics, by examining metabolic profiles, offers valuable insights into disease progression and drug efficacy. Microbiomics, which analyzes the body’s microbiome, is increasingly recognized for its impact on health outcomes and pharmacogenomics. Bioinformatics integrates large datasets across all these areas, enabling researchers and clinicians to process and interpret complex biological information efficiently. This segment has seen remarkable growth, propelled by technological advancements, increasing healthcare costs, and a growing emphasis on personalized medicine. The emphasis on precision medicine within the US healthcare system reflects the recognition of these technologies as essential tools in combatting diseases more precisely and effectively, enhancing patient care while aiming for better health outcomes across diverse populations. ### **Precision Medicine Market End Use Insights** The End Use segment of the US Precision Medicine Market plays a vital role in shaping the industry's growth and innovation landscape. Pharmaceutical Companies are significant players, driving advancements through personalized drug development that aligns with genetic profiles, enhancing treatment efficacy and reducing adverse effects. Healthcare Institutions benefit immensely from precision medicine, as tailored therapies improve patient outcomes and facilitate targeted interventions, ultimately leading to cost reductions in long-term care. Research Organizations contribute by conducting pivotal studies that inform clinical practices and validate therapeutic approaches, while Diagnostic Laboratories are essential for developing precise tests that enable the accurate assessment of individual patient needs. The interconnectedness of these segments underscores their collective importance in fostering advancements in precision medicine, ensuring that treatments are not only effective but also accessible to a broader patient population. The continuous evolution of these areas reflects the dynamic nature of the US Precision Medicine Market, driving innovations and reshaping healthcare delivery through data-driven insights. ### **Precision Medicine Market Product Insights** The US Precision Medicine Market has seen a growing focus on the Product segment, which comprises various essential areas, including Diagnostic Tools, Therapeutics, Genetic Testing, and Data Analytics Solutions. Diagnostic Tools play a crucial role in identifying specific biomarkers, allowing healthcare providers to tailor treatments for individual patients. In the area of Therapeutics, innovative therapies that target genetic variations are advancing patient outcomes, addressing diseases more effectively than traditional methods. Genetic Testing is increasingly becoming vital for understanding hereditary conditions and guiding treatment decisions, fostering a more personalized healthcare approach. Furthermore, Data Analytics Solutions are instrumental in managing the vast amounts of data generated in precision medicine, enabling healthcare professionals to derive actionable insights from clinical and genomic data. This segment is experiencing significant advancements, driven by the demand for customized healthcare solutions and improved patient management. The US, being at the forefront of technological innovations, is witnessing a robust expansion in these areas due to supportive government policies and a well-established healthcare infrastructure, paving the way for enhanced market growth in precision medicine. Market players are investing in Research and Development to stay competitive, ensuring the continuous evolution of these products to meet the urgent needs of patients and healthcare providers alike. ## **US Precision Medicine Market Key Players and Competitive Insights** The US Precision Medicine Market is a rapidly evolving sector characterized by innovative technologies and a compelling focus on individualized approaches to healthcare. As it stands, the market is witnessing a surge in interest from various stakeholders, including pharmaceutical companies, biotechnology firms, academic institutions, and healthcare providers. Competitive insights in this landscape reveal that companies are increasingly leveraging genomic and molecular profiling to deliver tailored therapeutic options. The emphasis on data-driven treatments is reshaping traditional medical practices, resulting in enhanced patient outcomes and creating new market opportunities. The interplay of regulatory frameworks, technological advancements, and the pressing demand for personalized healthcare solutions are critical factors influencing the competitive landscape. ### **Foundation Medicine** Foundation Medicine has established itself as a leading entity in the US Precision Medicine Market, primarily known for its robust portfolio of genomic profiling solutions. The company specializes in advanced cancer diagnostics, providing insights that aid healthcare providers in making informed decisions regarding personalized treatment options. Foundation Medicine's strengths lie in its extensive database of genomic alterations, collaborations with leading healthcare institutions, and a commitment to innovation that keeps it at the forefront of precision oncology. The company has successfully integrated its services into clinical workflows, which bolsters its presence in the oncology market. Furthermore, its partnerships and collaborations elevate its visibility and enable it to expand its reach within the competitive landscape of precision medicine. ### **Bristol Myers Squibb** Bristol Myers Squibb is another significant player in the US Precision Medicine Market, recognized for its innovative biopharmaceutical solutions and commitment to advancing human health through groundbreaking therapies. The company offers a range of key products and services that cater to the precision medicine sector, particularly focusing on oncology, immunology, and cardiovascular diseases. Bristol Myers Squibb's strengths include its powerful research and development pipeline, which is enhanced by strategic mergers and acquisitions that bolster its capability to deliver targeted therapies. The company's collaborations with academic institutions and research organizations further emphasize its commitment to transforming healthcare through precision medicine. In the competitive landscape, Bristol Myers Squibb continues to strengthen its market presence by innovating and expanding its portfolio, positioning itself as a leader in tailoring treatment solutions to individual patient needs across the US. ### **Key Companies in the US Precision Medicine Market Include** ## **US Precision Medicine Market Industry Developments** The US Precision Medicine Market has seen several notable advancements in recent months. Foundation Medicine has continued to enhance its genomic profiling services, striving to personalize cancer treatment. Bristol Myers Squibb announced promising trial results regarding a new immunotherapy for lung cancer, which could significantly impact treatment paradigms. Meanwhile, Amgen and Pfizer are expanding their collaborations focusing on targeted therapies that leverage genetic insights. Current affairs indicate an increasing investment in Research and Development by Roche and Thermo Fisher Scientific, as they aim to innovate precision diagnostics. Notably, Johnson and Johnson has been advancing its biomarker identification efforts. In terms of mergers and acquisitions, Novartis completed the acquisition of a biotech firm specializing in gene therapies in September 2023, and Genentech has also recently partnered with Guardant Health to enhance their comprehensive genomic profiling capabilities effective August 2023. The ongoing investments and evolving partnerships among these key players, such as the growing commitment by GSK in genomics, contribute to a burgeoning market valuation, emphasizing the critical role of precision medicine in contemporary healthcare in the United States. Major happenings from earlier, such as the United States Precision Medicine Initiative launch in 2015, laid the groundwork for ongoing advancements across the sector. ## **US Precision Medicine Market Segmentation Insights** ### **Precision Medicine Market Application Outlook** ### **Precision Medicine Market Technology Outlook** ### **Precision Medicine Market End Use Outlook** ### **Precision Medicine Market Product Outlook** ## Market Drivers ### Supportive Reimbursement Policies Supportive reimbursement policies are emerging as a vital driver for the precision medicine market. As insurers recognize the value of personalized medicine, they are increasingly willing to cover the costs associated with genetic testing and targeted therapies. This shift in reimbursement practices is likely to enhance patient access to precision treatments, thereby expanding the us market. In 2025, it is anticipated that reimbursement for precision medicine services will increase by approximately 20%, further solidifying the precision medicine market. Such policies not only encourage healthcare providers to adopt innovative therapies but also foster a more favorable environment for market growth. ### Increased Investment in Biotechnology Investment in biotechnology is a significant driver of the precision medicine market. Venture capital funding and public investments are increasingly directed towards biotech firms that focus on developing precision therapies. In 2025, the biotechnology sector is expected to attract over $50 billion in investments, with a substantial portion allocated to precision medicine initiatives. This influx of capital is likely to accelerate the development of novel therapies and diagnostic tools, thereby enhancing the precision medicine market. As a result, the us market is poised for rapid growth, with new entrants and established companies alike striving to capitalize on this trend. ### Growing Prevalence of Chronic Diseases The rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is a critical driver of the precision medicine market. As these conditions become more common, there is an increasing need for targeted therapies that can address the specific genetic and molecular characteristics of individual patients. In the US, chronic diseases account for approximately 70% of all deaths, underscoring the urgent need for innovative treatment solutions. This trend is likely to propel the precision medicine market forward, as healthcare providers seek to implement more effective and personalized treatment strategies to combat these diseases. ### Advancements in Diagnostic Technologies Advancements in diagnostic technologies are significantly influencing the precision medicine market. Innovations such as next-generation sequencing and liquid biopsy are enabling more accurate and timely diagnoses, which are essential for the effective implementation of precision therapies. The us industry for diagnostic tools is expected to grow at a CAGR of around 15% through 2026, reflecting the increasing reliance on advanced diagnostics in the precision medicine market. These technologies not only enhance patient outcomes but also facilitate the identification of suitable candidates for targeted therapies, thereby driving market growth. ### Rising Demand for Personalized Treatments The precision medicine market is experiencing a notable increase in demand for personalized treatments, driven by a growing awareness among patients and healthcare providers. Patients are increasingly seeking therapies tailored to their unique genetic profiles, which enhances treatment efficacy and minimizes adverse effects. This shift towards personalized care is reflected in market data, indicating that the us market is projected to reach approximately $100 billion by 2026, growing at a CAGR of around 11%. As healthcare systems adapt to this demand, the precision medicine market is likely to see further investments in research and development, ultimately leading to more innovative treatment options. ## Future Outlook The [Precision Medicine Market](https://www.marketresearchfuture.com/reports/precision-medicine-market-925) is projected to grow at a 9.97% CAGR from 2025 to 2035, driven by advancements in genomics, personalized therapies, and increased healthcare investments. **New opportunities:** - Development of AI-driven diagnostic tools for personalized treatment plans. Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)services integrating precision medicine solutions. Partnerships with biotech firms for innovative drug development initiatives. By 2035, the precision medicine market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Oncology (Largest) vs. Cardiology (Fastest-Growing) In the US precision medicine market, the application segments of oncology and cardiology play pivotal roles. Oncology leads as the largest segment, driven by a robust pipeline of targeted therapies and precision treatment options. This segment accounts for a significant portion of the overall market share, reflecting heightened investments in cancer genomics and personalized medicine technologies. Cardiology, while currently smaller than oncology, is recognized as the fastest-growing segment. This growth is fueled by advancements in genetic testing and the development of personalized treatment regimens for cardiovascular diseases. Increased awareness of the benefits of precision medicine in managing heart conditions is propelling cardiology's rapid expansion, making it a critical area for future developments in the us industry. Oncology (Dominant) vs. Rare Diseases (Emerging) Oncology remains the dominant application segment in the US precision medicine market, characterized by its extensive research and development in molecular profiling and targeted therapies. This segment benefits from a strong focus on personalized treatments that minimize side effects and increase efficacy for various types of cancer. In contrast, rare diseases are emerging as a significant area of interest, as advancements in genomic medicine pave the way for personalized therapies tailored to individuals with specific genetic disorders. The motivation to address unmet medical needs in this niche market is driving innovation, leading to novel therapeutic options and improved quality of life for patients. Both segments are essential in showcasing the transformative potential of precision medicine. ### By Technology: Genomics (Largest) vs. Bioinformatics (Fastest-Growing) The US[precision medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925) market demonstrates a diverse landscape across various technologies. Genomics remains the largest segment, capturing a significant share due to advancements in genetic sequencing and analysis. Following closely are proteomics and metabolomics, which are gradually establishing their prominence as healthcare providers increasingly leverage these technologies to personalize treatments. In contrast, microbiomics and bioinformatics, while currently smaller in market share, are rapidly gaining traction as the integration of big data in healthcare continues to grow. Growth trends indicate that bioinformatics is currently the fastest-growing segment, driven by the need for advanced data analytics and interpretation in precision medicine. Healthcare systems are investing heavily in bioinformatics solutions to handle the vast amounts of genetic and clinical data, facilitating improved patient outcomes. Meanwhile, the growth of genomics is also noteworthy, as ongoing research and collaborations are likely to enhance its market position. As a result, these technologies are expected to converge, driving further innovation in tailored therapies. Genomics (Dominant) vs. Bioinformatics (Emerging) Genomics serves as the dominant technology in the US precision medicine market, underpinned by its foundational role in understanding genetic predispositions and their implications for health. This segment yields insights that are critical for drug development and personalized treatment plans, making it integral to modern healthcare dynamics. On the other hand, bioinformatics is an emerging technology that plays a vital role in supporting genomics through data management and analysis. As the volume of healthcare data expands, bioinformatics offers tools for translating complex biological data into actionable healthcare strategies, thus paving the way for innovative solutions that enhance medical decision-making and patient care. ### By End Use: Pharmaceutical Companies (Largest) vs. Healthcare Institutions (Fastest-Growing) In the US precision medicine market, Pharmaceutical Companies hold the largest share, driven by their extensive use of precision therapies and innovations. This segment capitalizes on advanced genomics and personalized treatment plans to cater to specific patient needs. In contrast, Healthcare Institutions, while currently smaller in share, are growing rapidly as they increasingly recognize the value of precision medicine in enhancing patient outcomes and operational efficiency. The growth trends in this segment reveal a strong emphasis on integrative healthcare solutions, with Research Organizations and Diagnostic Laboratories playing crucial supportive roles. These entities contribute to the advancement of precision medicine through innovative research and development. Furthermore, the swift adoption of precision medicine technologies in clinical settings is supported by favorable regulatory environments and collaborations across stakeholders, driving significant market growth. Pharmaceutical Companies (Dominant) vs. Diagnostic Laboratories (Emerging) Pharmaceutical Companies are the dominant players in the US precision medicine market, focusing on the development and commercialization of targeted therapies tailored to genetic profiles. Their expertise in leveraging cutting-edge research translates into effective treatment regimens, solidifying their market leadership. In contrast, Diagnostic Laboratories are emerging as vital contributors, providing essential services that support personalized medicine initiatives. These laboratories offer advanced testing and analysis, which are imperative for the successful implementation of precision therapies. As the demand for customized treatment increases, Diagnostic Laboratories are expanding their capabilities, making them critical to the precision medicine landscape. Their growth is further accentuated by technological advancements and increased collaboration with pharmaceutical firms to enhance diagnostic accuracy. ### By Product: Diagnostic Tools (Largest) vs. Genetic Testing (Fastest-Growing) In the US precision medicine market, Diagnostic Tools dominate with the largest share, reflecting the increasing demand for personalized approaches to disease detection and treatment. Following closely, Genetic Testing has emerged as a fast-growing segment, driven by advances in genomics and the rising consumer awareness regarding genetic health risks. Consequently, the overall market is experiencing dynamic shifts as investments in these areas continue to support innovation and accessibility. Growth trends in the segment indicate a robust expansion in both Diagnostic Tools and Genetic Testing, primarily fueled by technological advancements and regulatory support. The integration of artificial intelligence and machine learning into diagnostic processes has enhanced accuracy and efficiency, paving the way for quicker results, while Genetic Testing is accelerated by increasing applications in preventive healthcare. A growing patient-centric approach is further propelling these trends, as more individuals seek personalized health insights that cater to their unique genetic backgrounds. Diagnostic Tools (Dominant) vs. Genetic Testing (Emerging) Diagnostic Tools are positioned as the dominant force in the US precision medicine market, characterized by their essential role in identifying diseases through advanced imaging techniques and biomarker analysis. Their widespread adoption is largely due to the increasing focus on early detection and personalized treatment pathways. In contrast, Genetic Testing represents an emerging segment, driven by the rapid development in genetic research and consumer demand for tailored healthcare solutions. This segment is witnessing exponential growth as it leverages cutting-edge technologies to assess genetic predispositions and inform treatment plans. Both segments are critical, but their market dynamics reveal distinct trends that shape the future landscape of personalized medicine. ## Competitive Benchmarking The precision medicine market is currently characterized by a dynamic competitive landscape, driven by rapid advancements in genomics, biotechnology, and data analytics. Key players are increasingly focusing on innovation and strategic partnerships to enhance their product offerings and market reach. For instance, Illumina (US) has positioned itself as a leader in genomic sequencing technologies, emphasizing the development of next-generation sequencing (NGS) platforms that cater to both clinical and research applications. Similarly, Thermo Fisher Scientific (US) is leveraging its extensive portfolio to integrate precision medicine solutions into its existing workflows, thereby enhancing operational efficiency and customer engagement. The us industry structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. This fragmentation is indicative of a competitive environment where companies are not only competing on technological advancements but also on their ability to deliver tailored solutions to diverse customer needs. The collective influence of these key players shapes the global market dynamics, as they engage in strategic collaborations and mergers to bolster their capabilities. In September 2025, Roche (CH) announced a strategic partnership with a leading AI firm to enhance its diagnostic capabilities in precision oncology. This collaboration aims to integrate artificial intelligence into Roche's existing diagnostic platforms, potentially revolutionizing the way cancer is diagnosed and treated. The strategic importance of this move lies in Roche's commitment to staying at the forefront of technological innovation, which is crucial in a rapidly evolving market. In October 2025, Abbott Laboratories (US) launched a new line of personalized diagnostic tests aimed at improving patient outcomes in chronic disease management. This initiative underscores Abbott's focus on expanding its precision medicine portfolio, reflecting a broader trend towards personalized healthcare solutions. By investing in tailored diagnostics, Abbott is likely to enhance its competitive positioning and address the growing demand for individualized treatment options. Furthermore, in August 2025, GRAIL (US) received FDA approval for its multi-cancer early detection test, marking a significant milestone in the field of precision medicine. This approval not only validates GRAIL's innovative approach but also positions the company as a key player in the early detection of cancers, which is increasingly recognized as a critical factor in improving survival rates. The strategic implications of this approval could lead to expanded market opportunities and partnerships with healthcare providers. As of November 2025, current trends in the precision medicine market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming increasingly vital, as companies seek to combine their strengths to navigate the complexities of the us industry. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in the future. ## Recent News & Developments The US Precision Medicine Market has seen several notable advancements in recent months. Foundation Medicine has continued to enhance its genomic profiling services, striving to personalize cancer treatment. Bristol Myers Squibb announced promising trial results regarding a new immunotherapy for lung cancer, which could significantly impact treatment paradigms. Meanwhile, Amgen and Pfizer are expanding their collaborations focusing on targeted therapies that leverage genetic insights. Current affairs indicate an increasing investment in Research and Development by Roche and Thermo Fisher Scientific, as they aim to innovate precision diagnostics. Notably, Johnson and Johnson has been advancing its biomarker identification efforts. In terms of mergers and acquisitions, Novartis completed the acquisition of a biotech firm specializing in gene therapies in September 2023, and Genentech has also recently partnered with Guardant Health to enhance their comprehensive genomic profiling capabilities effective August 2023. The ongoing investments and evolving partnerships among these key players, such as the growing commitment by GSK in genomics, contribute to a burgeoning market valuation, emphasizing the critical role of precision medicine in contemporary healthcare in the United States. Major happenings from earlier, such as the United States Precision Medicine Initiative launch in 2015, laid the groundwork for ongoing advancements across the sector. ## Report Scope | MARKET SIZE 2024 | 7.83(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 8.61(USD Billion) | | MARKET SIZE 2035 | 22.27(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.97% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Abbott Laboratories (US), Qiagen (DE), Bristol-Myers Squibb (US), GRAIL (US), Foundation Medicine (US), Novartis (CH) | | Segments Covered | Application, Technology, End Use, Product | | Key Market Opportunities | Integration of artificial intelligence in diagnostics enhances personalized treatment strategies in the precision medicine market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the precision medicine market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the us market valuation of the US precision medicine market in 2024?** A: The US Market valuation was $7.83 Billion in 2024. **Q: What is the projected market valuation for the US precision medicine market by 2035?** A: The projected valuation for 2035 is $22.27 Billion. **Q: What is the expected CAGR for the US precision medicine market during the forecast period 2025 - 2035?** A: The expected CAGR is 9.97% during the forecast period 2025 - 2035. **Q: Which application segment is expected to show the highest growth in the US precision medicine market?** A: The oncology segment is anticipated to grow from $2.35 Billion to $6.75 Billion. **Q: What are the key technologies driving the US precision medicine market?** A: Key technologies include genomics, proteomics, and bioinformatics, with genomics projected to grow from $2.5 Billion to $7.5 Billion. **Q: Which end-use segment is projected to have the largest market share in 2035?** A: Pharmaceutical companies are expected to dominate, growing from $2.35 Billion to $6.75 Billion. **Q: What product category is anticipated to experience significant growth in the US precision medicine market?** A: Therapeutics is projected to grow from $2.35 Billion to $6.78 Billion. **Q: Who are the leading players in the US precision medicine market?** A: Key players include Illumina, Thermo Fisher Scientific, and Roche, among others. **Q: What is the growth potential for the infectious diseases segment in the US precision medicine market?** A: The infectious diseases segment is expected to grow from $1.78 Billion to $4.52 Billion. **Q: How does the us market for genetic testing compare to other product categories in 2035?** A: Genetic testing is projected to grow from $2.05 Billion to $5.92 Billion, indicating strong demand. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-precision-medicine-market-14662*